Actavis launches first generic equivalent of Requip XL (ropinirole extended-release tablets) (PRNewswire) - May 18, 2012 - Actavis has received US FDA approval of ropinirole extended-release tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip XL; Actavis believes this is first generic Requip XL available in US
Generic approval • Parkinson's Disease
|
|
Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip® XL. Actavis believes this is the first generic Requip® XL available in the US. Distribution of the product has commenced.
Requip® XL, 2mg, 4mg, 6mg, 8mg and 12mg, had US sales of approximately $59.4 million for the 12 months ending December 31, 2011, according to IMS Health.
|